Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
BUSINESS
Choseido Revamps Management, Sacks President Harada over GMP Violations
Choseido Pharmaceutical said on October 25 that it has revamped its management by dismissing President Hideaki Harada and other senior executives over GMP violations that triggered a 31-day business suspension order earlier this month. The company revealed the management change…
To read the full story
Related Article
- Choseido Resumes Operations after 31-Day Biz Suspension
November 12, 2021
- Choseido Suspended from JGA for 5 Years after Biz Suspension Order
October 15, 2021
- Lack of Management Response, Tight Manufacturing Plans to Blame in Choseido Issue: Report
October 12, 2021
- Choseido Woes Cast Clouds on Generic Inroads in Tokushima, Worst Player in Penetration
October 12, 2021
- JGA Vows Strict Response to Choseido’s Biz Suspension Order
October 12, 2021
- Choseido Hit by Biz Suspension of Up to 31 Days over Manufacturing Flaws
October 11, 2021
BUSINESS
- Chugai’s FoundationOne Liquid Wins Approval as Tabrecta CDx
May 29, 2023
- Seikagaku Nets Positive Data in Additional US PIII for Herniated Disk Drug
May 29, 2023
- Hutchmed’s Colorectal Cancer Med Gets FDA’s Priority Review: Takeda
May 29, 2023
- PharmaEssentia’s 1st Product to Hit Japan Market on June 1
May 29, 2023
- Pfizer Japan Files RSV Vaccine for 60 Years of Age and Older
May 29, 2023
President Joe Biden enacted the Inflation Reduction Act (IRA) on August 16, 2022, significantly affecting Medicare prescription drug coverage and introducing targeted changes to Medicaid, the Children’s Health Insurance Program, and private health insurance. In January 2023, the Centers for…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…